Cholinesterase, Serum, with Dibucaine Inhibition
Test Summary
The Pseudocholinesterase phenotype can be determined by analysis of Pseudocholinesterase and the percent inhibition by Dibucaine. Approximately 96% of the population has normal activity, approximately 4% will exhibit decreased activity that leads to prolonged paralysis following use of succinylcholine, and 1 in 3000 patients will exhibit severe, prolonged paralysis following anesthetic exposure.
Aliases
- N/A
Specimen Collection
Special Instructions
N/A
Preferred Specimen
1 mL serum
Minimum Volume
0.5 mL
Instructions
N/A
Patient Preparation
N/A
Storage
Plastic screw-cap vial
Transport Temperature
Room temperature
Specimen Stability
- Room temperature: 21 days
- Refrigerated: 21 days
- Frozen: 30 days
Limitations
Elevated values, caused by the presence of young RBCs and reticulocytes, may mask acetylcholinesterase inhibition.
Other Acceptable Specimens
N/A
Unacceptable Specimens
Gross hemolysis
Order Code
CHLDIB
EPIC (Premier) Code
LAB3658
Includes
N/A
CPT Code
- 82480
- 82638
Billing Code
- 670177, 670178
CPT Statement
Methodology
Kinetic Spectrophotometry (KS)
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Physician Attestation of Informed Consent
N/A
Testing Laboratory
Quest Diagnostics Nichols Institute
14225 Newbrook Drive
Chantilly VA, 20153
14225 Newbrook Drive
Chantilly VA, 20153
Department
Reference Testing
Reference Range
| Cholinesterase, Serum | |
| Male | 3342-7586 IU/L |
| Female | 2673-6592 IU/L |
| Dibucaine Number | 81.6-88.3 % Inhibition |
Cholinesterase with Dibucaine Inhibition
| Phenotype | % Inhibition |
| U | 83.6 |
| A* | 19.9 |
| AS* | 20.7 |
| S1* | 5.3 |
| S2* | 67.6 |
| F* | 71.8 |
| AF* | 60.2 |
| FS* | 76.7 |
| UA | 72.7 |
| UF | 79.8 |
| US | 84.4 |
Setup Schedule / Expected Turnaround Time
Daily; Report available: 1 day
Specimen Collection
Special Instructions
N/A
Preferred Specimen
1 mL serum
Minimum Volume
0.5 mL
Instructions
N/A
Patient Preparation
N/A
Storage
Plastic screw-cap vial
Transport Temperature
Room temperature
Specimen Stability
- Room temperature: 21 days
- Refrigerated: 21 days
- Frozen: 30 days
Limitations
Elevated values, caused by the presence of young RBCs and reticulocytes, may mask acetylcholinesterase inhibition.
Other Acceptable Specimens
N/A
Unacceptable Specimens
Gross hemolysis
Result Information
Methodology
Kinetic Spectrophotometry (KS)
Testing Laboratory
N/A
Reference Range
| Cholinesterase, Serum | |
| Male | 3342-7586 IU/L |
| Female | 2673-6592 IU/L |
| Dibucaine Number | 81.6-88.3 % Inhibition |
Cholinesterase with Dibucaine Inhibition
| Phenotype | % Inhibition |
| U | 83.6 |
| A* | 19.9 |
| AS* | 20.7 |
| S1* | 5.3 |
| S2* | 67.6 |
| F* | 71.8 |
| AF* | 60.2 |
| FS* | 76.7 |
| UA | 72.7 |
| UF | 79.8 |
| US | 84.4 |
Setup Schedule / Expected Turnaround Time
Daily; Report available: 1 day